{
  "image_filename": "figure_p2_det_1_000.png",
  "image_path": "CDC_Influenza_vaccines/extracted/figures/figure_p2_det_1_000.png",
  "image_type": "Figure",
  "page_number": 2,
  "block_id": "det_1_000",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "A table listing trade names (manufacturers), presentations, age indications, antigen content per dose, administration route, and mercury content for quadrivalent influenza vaccines, including Fluad Quadrivalent (Seqirus), Flublok Quadrivalent (Sanofi Pasteur), and FluMist Quadrivalent (AstraZeneca). does not support the claim because the table only provides formulation and dosing details and does not mention any pivotal trial or comparison against Fluarix Quadrivalent standard-dose vaccine.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table listing trade names (manufacturers), presentations, age indications, antigen content per dose, administration route, and mercury content for quadrivalent influenza vaccines, including Fluad Quadrivalent (Seqirus), Flublok Quadrivalent (Sanofi Pasteur), and FluMist Quadrivalent (AstraZeneca).",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table only provides formulation and dosing details and does not mention any pivotal trial or comparison against Fluarix Quadrivalent standard-dose vaccine.",
    "confidence_notes": null
  }
}